Company Profile
Argenx Stock Price, News & Analysis
- Ticker:
- ARGX
- Exchange:
- NASDAQ
- Sector:
- Antibody Drugs
- Location:
- Ghent, Belgium and listed in the U
Stock performance
875.30 USD (+0.85%)
Close
Last updated: August 6, 2026
49.9B USD
Market cap
Why the stock is moving
The latest company update was “argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.”. ARGX changed 0.85% and closed at $875.30 on Aug 6, 2026, indicating a relatively limited closing-price reaction to this company update.
Company overview
Global Immunology Company
Argenx develops therapies for severe autoimmune diseases. Its core commercial asset, VYVGART/efgartigimod, targets FcRn to reduce circulating IgG autoantibodies and has established a commercial base in generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and selected regional indications such as primary immune thrombocytopenia.
VYVGART Expansion Strategy
The company is expanding VYVGART into ocular myasthenia gravis, autoimmune myositis, primary immune thrombocytopenia, Sjögren’s disease, and Graves’ disease. VYVGART Hytrulo, the subcutaneous formulation, broadens the franchise through more convenient administration.
Global Commercial Franchise
VYVGART is commercialized across multiple regions and formulations, with the expanded U.S. label covering all adult gMG serotypes. The franchise provides argenx with an established commercial organization that can support additional indications and future immunology assets.
Empasiprubart as a Second Franchise
Empasiprubart, a complement C2-targeting antibody, represents argenx’s second potential pipeline-in-a-product. It is being studied in multifocal motor neuropathy, CIDP, delayed graft function, and combination therapy with VYVGART in gMG.
Earlier Immunology Pipeline
Additional programs include next-generation FcRn candidates ARGX-213 and ARGX-124, MuSK agonist adimanebart, anti-IgA antibody ARGX-121, and other candidates emerging from the company’s Immunology Innovation Program.
Vision 2030 Framework
Argenx’s long-term strategy targets 50,000 patients treated globally, ten labeled indications, and five pipeline candidates in registrational development by 2030. The framework links continued VYVGART expansion with the creation of multiple independent immunology franchises.
Future catalysts
Topline data from the registrational ALKIVIA study of VYVGART in autoimmune myositis are expected in the third quarter of 2026.
Topline data from the registrational EMPASSION study of empasiprubart in multifocal motor neuropathy are expected in the fourth quarter of 2026.
Topline results from the ADVANCE-NEXT study in primary ITP are expected in the first half of 2027, followed by UNITY data in Sjögren’s disease in the second half of 2027.
A VYVGART SC autoinjector is expected to launch across all approved indications in 2027.
A registrational study of adimanebart in congenital myasthenic syndromes, a Phase 2 study of ARGX-121 in IgA nephropathy, and Phase 1 studies of ARGX-118 and ARGX-125 are planned to advance during 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Argenx (ARGX)?
Argenx (ARGX) most recently closed at 875.30 USD, a +0.85% move versus the previous session.
What is the market cap of Argenx (ARGX)?
Argenx currently has a market capitalization of 49.9B USD on BioPharmSignal.
What does Argenx do?
Global Immunology Company Argenx develops therapies for severe autoimmune diseases. Its core commercial asset, VYVGART/efgartigimod, targets FcRn to reduce circulating IgG autoantibodies and has established a commercial base in generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and selected regional indications such as primary...
On which exchange is ARGX stock listed?
Argenx (ARGX) is associated with NASDAQ, Ghent, Belgium and listed in the U, Antibody Drugs.
What is ARGX-213?
Earlier Immunology Pipeline Additional programs include next-generation FcRn candidates ARGX-213 and ARGX-124, MuSK agonist adimanebart, anti-IgA antibody ARGX-121, and other candidates emerging from the company’s Immunology Innovation Program.
Which conditions is Argenx targeting with ARGX-213?
Argenx is associated with immunology based on its company overview and current catalyst commentary.
How does Argenx describe recent progress with ARGX-213?
Topline data from the registrational ALKIVIA study of VYVGART in autoimmune myositis are expected in the third quarter of 2026. Topline data from the registrational EMPASSION study of empasiprubart in multifocal motor neuropathy are expected in the fourth quarter of 2026. Topline results from the ADVANCE-NEXT study in primary ITP are expected in the first...
What is ARGX-124?
Earlier Immunology Pipeline Additional programs include next-generation FcRn candidates ARGX-213 and ARGX-124, MuSK agonist adimanebart, anti-IgA antibody ARGX-121, and other candidates emerging from the company’s Immunology Innovation Program.